Pharmadrug Inc. (G11)

Overview

Pharmadrug Inc., initially known as Aura Health Inc., is a rebranded entity that was established in October 2019. Based in Toronto, Canada, it operates as a specialty pharmaceutical company with a focus on the research, development, and commercialization of controlled substances and natural medicines. Its primary areas of interest include psychedelics, cannabis, and naturally-derived approved drugs. Through strategic partnerships and research agreements with notable institutions such as the University of Michigan and Johns Hopkins University, Pharmadrug aims to explore the potential and applications of substances like N, N-dimethyltryptamine (DMT) and cepharanthine in medical science. Additionally, it ventures into the European market by importing and distributing medical cannabis to pharmacies, particularly in Germany and the broader European Union. Furthermore, the company is involved in vertically integrating and promoting the use of functional as well as psilocybin mushrooms through its ownership and operation of Super Smart.

Products and Services

• Research and Development in Controlled Substances and Natural Medicines: Focused on leveraging the medicinal value of psychedelics, cannabis, and naturally-derived approved drugs. Pharmadrug invests in understanding the therapeutic potential of these substances through comprehensive research and development practices.

• Medical Cannabis Distribution: Specializes in importing and distributing medical cannabis to pharmacies across the European Union, with a significant focus on the German marketplace. This effort aims to provide quality-controlled cannabis products for therapeutic use under regulated conditions.

• Functional and Psilocybin Mushroom Integration: Through the acquisition and operational management of Super Smart, Pharmadrug endeavours to lead in the emerging market for functional mushrooms and psilocybin mushrooms. The initiative seeks to explore and expand the utilization of these natural compounds for their health and therapeutic benefits.

• Partnerships for Clinical Research: Establishes and maintains strategic partnerships with prestigious research institutions, including the University of Michigan and Johns Hopkins University, to study and evaluate the effects and therapeutic potentials of substances like DMT and cepharanthine. These collaborations aim to pave the way for future clinical trials and the potential introduction of new treatments based on controlled substances and natural medicines.